The UK pharma giant AstraZeneca will invest $1.5 billion to build its first end-to-end antibody-drug conjugate (ADC) manufacturing facility in Singapore. The plant will be designed to manufacture all ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results